NCT04697407View on ClinicalTrials.gov

IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis

NACompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

May 23, 2023

Study Completion Date

May 23, 2023

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

Blood sampling

In all groups, 80 ml of blood will be collected. For patients, this will be done during routine cares.

BIOLOGICAL

CSF sampling

Only in both patients groups whom will have a CSF sampling in routine care, some CSF will be collected for the study in addition, with a limit of 5 ml for routine care and study.

Trial Locations (1)

Unknown

CHU Rennes, Rennes

All Listed Sponsors
lead

Rennes University Hospital

OTHER

NCT04697407 - IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis | Biotech Hunter | Biotech Hunter